Circulating LncPPARδ From Monocytes as a Novel Biomarker for Coronary Artery Diseases

To investigate long noncoding RNA NONHSAT112178 (LncPPAR delta) as a biomarker for coronary artery disease (CAD) in peripheral blood monocyte cells, RT-qPCR was performed to validate the microarray results, receiver operating characteristic curve was applied to study the potential of LncPPAR delta as a biomarker. Diagnostic models from LncPPAR delta alone or combination of risk factors were constructed by Fisher criteria. The expression of genes neighboring the LncPPAR delta gene was examined with RT-qPCR in THP-1 cell line treated with LncPPAR delta siRNA. Using a diagnostic model by Fisher criteria, the consideration of risk factors increased the optimal sensitivity from 70.00% to 82.00% and decreased the specificity from 94.00% to 78.00%. The consideration of risk factors also increased area under the receiver operating characteristic curve from 0.727 to 0.785 (P = 0.001), from 0.712 to 0.768 (P = 0.01), and from 0.769 to 0.835 (P = 0.07), in the original, training, and test sets, respectively. Finally, we found that the expression of peroxisome proliferator-activated receptor delta (PPAR delta), Adipose Differentiation-Related Protein (ADRP), and Angiopoietin-like 4 (ANGPTL4) were affected by LncPPAR delta silencing. Our present study indicated that LncPPAR delta, especially combined with risk factors, can be a good biomarker for CAD. LncPPAR delta regulates the expression of neighboring protein-coding genes, PPAR delta and its direct target genes ADRP and ANGPTL4.